




































































































































































In the last ten years the scientific community has 
devoted a consistent effort to identify the genetic basis 
of the most common age-related diseases, as they 
represent one of the most important public health and 
socio-economical burden all over the world and 
particularly in Western Countries. This challenge was 
mainly faced up by genome wide association studies 
(GWASs) based on microarray technology that allows 
the simultaneous analyses of hundred thousands of 
single nucleotide polymorphisms (SNPs), within the 
framework of the “common variant common disease” 
theory [1]. So far, more than 1,000 published GWASs 
reported significant associations of ~4,000 SNPs for 
more than 200 traits/diseases [2]. GWASs of age-
related, chronic human diseases often suffer from a lack 
of power to detect modest effects, which can to some 
extent explain why the identified genetic effects 
comprise only a small fraction of the estimated trait 
heritability. These limitations can be overcome simply 
by ever increasing sample size in order to achieve the 
necessary statistical power to detect variants with small 
effects, which is not always feasible. Moreover, in most 
cases the biological role/relevance of the genetic 
variants emerged from GWASs is still unclear. In past, 
several strategies were proposed to increase detection 
power without affecting the cohort size, such as the use 
of genetically isolated populations characterized by a 
reduced genetic diversity that facilitate the discovery of 
relevant loci for complex diseases [3,4]. To date this 
approach has not been successful to boost the discovery 
of relevant associations with complex traits [5]. Thus, 
there is an urgent need for an effective strategy to obtain 
biological insights from the genetic knowledge derived 



















The aim of this study was to test the hypothesis that 
GWASs sensitivity can be boosted by including 
extreme phenotypic groups. As a proof of principle 
study, we considered one of the major age-related 
diseases, i.e. type 2 diabetes (T2D). We applied a 
candidate gene approach to assess associations of a 
limited set of SNPs (31) in or nearby genes relevant for 
T2D, diabetes complications, metabolic diseases, 
telomere stability and age-related diseases. The extreme 
phenotypic groups we focused on are as follows: i) 
CENTENARIANS who reached the extreme limit of 
human life, escaping or largely postponing the major 
age-related diseases, including T2D, and who can be 
considered a paradigm of healthy aging [6]. In 
particular, a major characteristic of centenarians is their 
extraordinarily well preserved glucose metabolism. 
Aging is frequently associated with impaired glucose 
metabolism related to a raise in insulin resistance (IR), 
not fully compensated by a sufficient β-cell function. 
Such age-related metabolic changes are key risk factors 
for T2D and are associated with a variety of 
intermediate phenotypes (hypertension, atherosclerosis, 
obesity) strongly affecting morbidity, disability and 
mortality among elderly. In a pioneering study, Paolisso 
et al. [7], using an oral glucose tolerance test and 
euglycemic glucose clamp, showed that centenarians 
had a 2-h plasma glucose concentration that was lower 
than that of aged subjects but not different from adults, 
and an insulin-mediated glucose uptake higher than that 
reported for aged subjects but not different from that 
found in adults. In a subsequent study, involving a large 
cohort of individuals (age range: 28-111 years) 
carefully selected for health status, we showed that the 
age-related trajectories of IR and β-cell function 
increase with age (the increase of β-cell function is 
necessary to compensate for the raise in  IR).  However,  
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of IR and with a lower β-cell function emerge, 
indicating that in very old people lower IR does not 
require a compensatory increment in β-cell function, 
thus allowing to preserve endocrine pancreas secretion 
and to prevent the development of T2D [8]. On the 
whole, these results point towards IR and β-cell 
function as phenotypes under strong selective forces 
during aging, supporting the hypothesis that effective 
peripheral glucose disposal is pivotal in determining 
longevity. These observations are confirmed by studies 
from our and other groups showing that centenarians 
offspring and nonagenarian siblings have a better health 
status than subjects of the same cohort, without the 
parental extreme longevity [9], and a reduced risk of 
diabetes and an enhanced insulin sensitivity [10–14]. ii) 
PATIENTS WITH T2D PLUS ONE OR MORE 
COMPLICATIONS. The T2D patients included in the 
present study have been fully characterized from a 
phenotypical (clinical, biochemical, pharmacological, 
among others) point of view, and have been extensively 
studied regarding a variety of genetic [15–18] and non-
genetic factors. In particular, we showed that T2D 
patients undergo accelerated aging [19] and that IL-10 
polymorphisms [20], telomere length in peripheral 
blood cells [21] and mitochondrial DNA variants [22] 
are able to distinguish between patients with and 
without complications. Thus, the presence of one or 
more micro- and macro-vascular complications not only 
represents the most severe and extreme phenotype of 
T2D, of relevance from a clinical and therapeutic point 
of view, but also has a biological counterpart which is 
























been compared with age-, gender- and geography-
matched control group.  
 
Here we considered a limited set of SNPs belonging to 
four classes of genetic variants: i) SNPs previously 
found associated with T2D by GWASs; ii) variants of 
genes involved in vascular pathology potentially 
involved in the development of T2D complications; iii) 
SNPs previously associated with metabolic diseases, 
including T2D; and iv) SNPs of genes relevant for 
telomere stability and involved in age-related diseases, 




In this study we analyzed the following cohorts 
described in depth in Methods: the whole cohort of 
diabetic patients (D), diabetic patients with 
complications (D+Co), diabetic patients who developed 
micro-vascular complications (D+microCo), diabetic 
patients who developed macro-vascular complications 
(D+macroCo), non diabetic controls matched for age, 
gender and geographical origin with diabetic patients 
(CTR) and centenarians (100+). These samples were 
tested for 31 SNPs, 22 of which passed the quality 
check. Results from association analyses are reported in 
Supplemental Materials (S1, S2, S3, S4). The most 
significant results involve TCF7L2 and ADIPOQ gene 
variants, which are reported in Table 1 and summarized 
in Figure 1. The comparisons that have been performed 
to test the effectiveness of our approach are reported in 


























analyzed.  TCF7L2  rs7903146  genotypic  and  allelic  frequencies  were  reported  according  to  the
decreasing of health/longevity and the increasing of T2D severity (from left to right). 
  



















































































































 Cohorts Gene SNP (ID) Allele/ Genotype 
Frequency 










D (1) vs 
100+ (2) ADIPOQ rs266729 G 24.6 31.6 5.89*10




































D (1) vs 
100+ (2) ADIPOQ rs266729 G/C      36.6 50.7 4.19*10















CC 30 47.5 
9.07*10-7 1.78  (1.41-2.26) 
Log-
additive TC 50 42.1 





CC 28.1 47.5 
5.47*10-6 1.89 (1.43-2.50) 
Log-
additive TC 51.1 42.1 





CC 23.4 47.5 
1.54*10-4 2.18 (1.45 -3.29) 
Log-
additive TC 53.1 42.1 





CC 29.1 47.5 
3.30*10-4 1.84 (1.31 -2.58) 
Log-
additive TC 50.0 42.1 
TT 20.9 10.4 
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All diabetic patients (D) vs non diabetic controls 
(CTR) (classical approach of genetic association 
studies)  
 
Allelic and genotypic association analyses were 
performed on all diabetic patients vs the classical 
control group. Only TCF7L2 rs7903146 T-allele was 
associated with T2D with an odds ratio (OR) of 1.372 
per risk allele (95% CI 1.155-1.629) (Table 1). 
Genotypic association of the TCF7L2 rs7903146 was 
significantly detected (p_value = 1.415*10-4, OR = 1.63 
(95% CI 1.26-2.09)) under a dominant model (Table 1). 
 
All diabetic patients (D) vs centenarians (100+)  
 
Allelic and genotypic association analyses were 
performed on all diabetic patients vs centenarians. Two 
nominal significant differences in the allelic frequencies 
of diabetic patients and centenarians were observed in 
the ADIPOQ rs266729 (OR = 0.706 (95% CI 0.551 - 
0.905), p_value = 5.89*10-3) and in TCF7L2 rs7903146. 

































associated with T2D with an OR = 1.775 per risk allele 
(95% CI 1.404-2.243, p_value = 1.35*10-6) (Table 1). 
TCF7L2 association was supported by genotypic 
association analysis. Indeed, significant differences in 
genotypic frequencies for rs7903146 were reported (OR 
= 1.78 (95% CI 1.41-2.26), p_value = 9.066*10-7) 
(Table 1). Genotypic association was found also for 
rs266729 in ADIPOQ gene (p_value = 4.19*10-4). 
 
Diabetic patients with complications (D+Co) vs non 
diabetic controls (CTR)  
 
Allelic and genotypic association analyses were 
performed on diabetic patients with at least one 
complication vs non diabetic controls. Only TCF7L2 
rs7903146 showed an allelic association with T2D 
susceptibility with an OR = 1.434 (95% CI 1.145-1.795, 
p_value = 1.66*10-3). No allelic associations were 
detected for the other SNPs genotyped (Supplementary 
Table 2). Genotypic association was observed for the 
same SNP with an OR = 1.79 (95% CI 1.28-2.52, 
































































D+Co vs 100+, D+macroCo vs 100+, and D+microCo 
vs 100+ (comparison between extreme phenotypes) 
  
Genotypic association analyses were performed on 
diabetic patients with at least one complication vs 
centenarians as a non-diabetes control group. When we 
compared D+Co vs 100+, D+macroCo vs 100+ and 
D+microCo vs 100+, the TCF7L2 rs7903146 resulted 
associated with T2D complicated patients with an OR = 
1.89 (95% CI 1.43-2.50, p_value = 5.473*10-6), 2.18 
(95% CI 1.45 -3.29, p value = 1.538*10-4) and 1.84 
(95% CI 1.31 - 2.58, p_value = 2.68*10-4), respectively 
(Table 1). In Figure 1 allele and genotype frequencies 
for rs7903146 were reported for each group considered. 
 
TCF7L2 interactome analysis 
 
Since our results confirmed a core role of TCF7L2 in 
T2D pathogenesis, consistent with its implicated role in 
T2D [23,24], an interactome analysis was performed. 
Tcf7l2 is a 619 AA-long transcription factor that 
participates in the Wnt signaling pathway and 
modulates MYC expression by binding to its promoter 
in a sequence-specific manner. The most central 
elements of the Tcf7l2 interactome are Ctbn1 (ranking 
1st) and Ep300, and, on a second order of importance, 
Csk21, Myc and Cebpa (Figure 2A). Among the whole 
Tcf7l2 interactome (including co-localization and 
physical association) with 30 elements (Figure 2), there 
is evidence of direct physical interactions 
(experimentally validated protein-protein interaction) of 
Tcf7l2 (Figure 2B, red line) with 12 other proteins 























analysis of the Tcf7l2 interactome was performed and 
the first ten OMIM diseases significantly connected to 




In the last few years GWASs provided a great amount 
of data regarding genetic risk factors for major age-
related diseases. Most variants identified so far confer 
relatively small increments in risk, and explain only a 
small proportion of the estimated trait heritability. 
Increasing sample size has been suggested as an answer 
to the missing heritability to increase sensitivity to 
detect variants with smaller effects. As an alternative 
for dramatically increasing cohort size, we tested a 
strategy that involves extreme phenotypes replicating a 
limited set of SNPs emerged and validated in GWASs. 
Individuals that are at the extreme ends of a trait 
distribution have been proposed for identifying variants 
that are rare but not private and that have modest to 
high effect sizes.  
 
We hypothesized that the frequencies of GWASs risk 
variants are inversely correlated with increasing health 
and longevity, and extreme phenotypic differences 
between cases and controls would allow detection of the 
genetic variants with the most relevant biological and 
clinical value at relatively small sample size. For an 
extreme-trait approach, accurate phenotyping will be of 
vital importance. Central to our approach is the 
“control” group. The proper “normal” controls, 
especially in relation to common age-related diseases, 
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“healthy” subjects are collected from different regions, 
characterized by peculiar lifestyle habits, population 
genetics, among others. To circumvent these 
difficulties, we propose to use centenarians as an 
additional, more informative and defined control group 
for studies on the genetic determinants of age-related 
diseases, and particularly to establish the biological and 
clinical relevance of the genetic variants emerged in 
GWASs. Indeed, this group can be considered as a 
“super-control”, as most centenarians achieved their 
remarkable age avoiding or largely postponing major 
age-related diseases, and thus, at variance with much 
younger controls, we can be sure that they never 
developed such diseases. We reasoned that if a given 
genetic variant emerged from GWASs and considered a 
statistically significant but “weak” risk factor for the 
disease of interest, is present at similar frequency in 
centenarians and in patients, its biological relevance is 
reasonably negligible. On the contrary, if a given 
genetic variant considered a risk factor for an age-
associated disease has a frequency much higher in 
patients than in centenarians, we can reasonably argue 
that this variant is a strong candidate to play a consistent 
biological role in the pathogenesis of the disease. We 
also assumed that centenarians, as the best model of 
healthy aging in humans [6], are a control group less 
blurred and undefined than the usually employed “age-
matched controls”. Moreover, in order to properly take 
into account the above-mentioned largely neglected 
clinical heterogeneity/severity of age-related diseases in 
studies on their genetic determinants, we focused on 
T2D and more specifically on two main groups of 
patients, i.e. those who did not develop complications 
and can enjoy a relatively long and acceptable quality of 
life, and those who developed one or more (micro– and 
macro-vascular) complications with a poorer quality of 
life. Accordingly, this approach allowed us to compare 
extreme phenotypes, i.e. centenarians on one side and 
T2D patients with severe complications on the other, 
thus maximizing possible genetic differences among 
patients and controls.  
 
Using this methodological approach on a total of 1,349 
individuals we tested 31 SNPs in or nearby 16 different 
genes that were previously strongly associated with 
T2D and metabolic diseases and that could be 
considered good candidate to play a role in T2D 
complications, on the basis of other large genetic 
studies.  
 
Our results indicate that most of the SNPs analyzed 
were not significantly associated with T2D, even when 
extreme groups of cases and controls were used. This 
somewhat unexpected result could be due to a lack of 
biological relevance in spite of their previously strong 
association signal in GWASs. Indeed, a major drawback 
of GWASs is the observation of many significant 
association signals from loci of weak effect. Therefore, 
we have to consider the possibility that such SNPs, 
despite having reached statistical significance in large 
GWASs, could have a weak biological relevance. 
Indeed, the presence of risk alleles at the same 
frequency in T2D patients with or without 
complications and in centenarians suggests that per se 
they do not represent a strong biological risk, being 
compatible with exceptional longevity, and that they 
likely necessitate to interact (epistatic effects) with 
(many) other risk alleles and/or specific environmental 
conditions to give a certain phenotype. Further studies, 
possibly in more than one population, are needed to test 
this possibility.  
 
The two SNPs that reached statistical significance in our 
study were ADIPOQ rs266729 and TCF7L2 rs7903146, 
the last one being the strongest. ADIPOQ encodes for 
adiponectin, the most abundant adipokine in human 
plasma. Low adiponectin levels are associated to IR and 
T2D [26–28] and the chromosome locus 3q27, where 
ADIPOQ is located, is linked to metabolic syndrome 
and T2D [29]. Several studies have investigated the 
association between ADIPOQ polymorphisms and T2D, 
but their results are controversial, probably due to 
differences in the size and in the composition of the 
analyzed cohorts [30] . To this regard it is interesting to 
note that the statistical significance of ADIPOQ 
rs266729, a polymorphism associated to decreased 
adiponectin levels, emerged only when T2D patients 
were compared with centenarians. Regarding TCF7L2 
rs7903146, localized in an intronic region of the gene, 
the most interesting findings were that the risk allele T 
and the genotype TT showed an increasing statistical 
significance, from modest genotypic association with 
the disease when all T2D patients (D) were compared 
with the age-matched controls (CTR) (OR=1.63; 95% 
CI 1.26-2.09) to intermediate values (OR=1.79; 95% CI 
1.28-2.52) when T2D patients with complications 
(D+Co) were compared with CTR. These OR values 
perfectly overlap OR previously described in literature 
[31] in GWASs that analyzed thousands of samples. 
Finally, the OR and p_values showed the most 
significant results when centenarians were compared 
with T2D patients, and a further increase in OR was 
observed when centenarians and patients with 
complications, the extreme phenotypes, were compared 
(D vs 100+: OR=1.78 (95% CI 1.41-2.26), 
p_value=9.066*10-7; D+Co vs 100+: OR=1.89 (95% CI 
1.43-2.50), p_value=5.473*10-6). It is important to note 
that the reverse is true for the C allele and the CC 
genotype. Notably, centenarians show not only the 
lowest frequency of T allele and TT genotype, but also 
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the highest frequency of C allele and CC genotype, 
which emerges as a robust protective longevity variant. 
These data also suggest that TCF7L2 rs7903146 is a 
robust genetic risk variant and indicate that further 
analyses based on the use of centenarians as super-
controls, possibly at genome wide level, are worthwhile 
to pursue in T2D study, and likely in other age-related 
diseases. TT genotype frequency was found to be higher 
not only in diabetic patients but also in patients with 
macro-vascular complications (Figure 1), reaching a 
frequency of 23.4%. These results demonstrate an 
important role of rs7903146 not only in T2D 
susceptibility but also in susceptibility to develop 
macro-vascular complications. Different studies 
investigated the relationship between macro-vascular 
complications, cardiovascular diseases and diabetes but 
the molecular mechanisms are still unknown [32–35].  
The TCF7L2 polymorphism rs7903146 was one of the 
first to be related to diabetes [36] and subsequently its 
association has been confirmed in several studies, placing 
it among the most reproducible markers of T2D [37–40]. 
Recent studies have shown that this SNP leads to 
conformational changes in chromatin structure according 
to the allele type. In particular the risk allele (T) induces 
an open conformation of the chromatin, resulting in an 
increased transcriptional activity and TCF7L2 mRNA 
levels [39,41,42]. It has been demonstrated that the 
increase of expression of TCF7L2 leads to a progressive 
reduction of glucose tolerance in vivo [43] . 
 
In order to gain information about the biological 
relevance of TCF7L2 gene, we performed an 
interactome analysis, which identified a complex 
network of interactions with Ctnb1 and Ep300 as the 
central elements. Ctnb1 is a Beta-catenin (adherens 
junction protein), critical for the establishment and 
maintenance of epithelial layers, and a key downstream 
component of the canonical Wnt signaling pathway. 
Ep300 is a histone acetyltransferase and regulates 
transcription via chromatin remodeling. Chromatin 
remodeling and epigenetic mechanisms seem to play a 
fundamental role in susceptibility to diabetes and 
related complications [44–47] even if mechanisms are 
not completely understood and further studies should be 
designed to clarify them. The in silico analysis suggests 
that Tcf7l2 interactome is involved in a variety of age-
related pathologies, such as Alzheimer's disease, 
cardiovascular diseases and colorectal cancer [48–52], 
all sharing vascular alterations, as a further support to 
the biological relevance of this gene and to the 
emerging idea that the same gene can play a major role 
in apparently different diseases [53]. 
 
On the whole, our data on TCF7L2 rs7903146 indicate 
that the frequency of T2D risk genotypes decreases 
according to the severity of the disease phenotype, 
supporting the assumption that centenarians represent a 
powerful and informative control group in association 
studies on T2D, a pathology characterized by significant 
clinical heterogeneity. Different authors have 
emphasized the problem of phenotypical heterogeneity 
of cohorts, which can seriously affect the ability to 
detect genetic associations [54]. Our data suggest that 
the use of relatively small numbers of cases and 
controls with extreme phenotypes (thus reducing sample 
heterogeneity) in genetic association studies of age-
related diseases can be successful in detecting 
significant associations as suggested by other authors 




Samples. A total of 1,349 individuals from 
Northern/Central Italy, including 562 T2D patients (D) 
(mean age: 65.76 ± 8.11) and 558 unrelated age-, 
gender- and geographically-matched controls (CTR) 
(mean age: 58.11 ± 12.40), and 229 centenarians (100+) 
(mean age: 105.0 ± 2.9) have been considered in this 
study. D and CTR subjects were collected by the 
Diabetology Unit, INRCA (National Institute on Health 
and Science on Aging) in Ancona (Italy). T2D 
diagnosis was made according to the American Diabetes 
Association Criteria (http://www.diabetes.org/). All 
patients were fully characterized from a clinical point of 
view and a large number of biochemical/endocronologi- 
cal parameters were measured. To avoid population 
stratification effects, only patients and controls with at 
least two generations of maternal ancestry from the 
Marche region (Central Italy) were included in this 
study. CTR subjects were carefully assessed and fully 
characterized according to the same protocol used for 
T2D patients, and a detailed clinical history was 
recorded in order to exclude the presence of T2D and of 
any other overt illness. Within the group of diabetic 
patients, N = 241 were affected by complications 
(D+Co), and in particular N = 110 had only micro-
vascular (D+microCo) and N = 64 had only macro-
vascular complications (D+macroCo). The main 
phenotypical and clinical characteristics of D and CTR 
are summarized in Table 2. 
 
The presence/absence of microvascular and 
macrovascular diabetic complications was assessed 
according to the following criteria: i) microvascular: 
diabetic retinopathy by fundoscopy through dilated 
pupils and/or fluorescence angiography; incipient 
nephropathy, defined by an excessive urinary albumin 
excretion (>30 mg/24 h) and a normal creatinine 
clearance; renal failure, detected as an estimated 
glomerular filtration rate >60 mL/min per 1.73 m2;  
  

































neuropathy established by electromyography; ii) 
macrovascular: ictus by clinical history; ischemic heart 
disease and acute myocardial infarction by clinical 
history and by resting electrocardiogram; peripheral 
vascular disease by clinical history and, for lower limbs, 
by ankle-brachial index. Hypertension was defined as a 
systolic blood pressure >140 mmHg and/or a diastolic 
blood pressure >90 mmHg. The values were measured 
while the subjects were sitting and confirmed at least 
three times. Overnight fasting venous blood samples 
from all subjects were collected from 8:00 to 9:00 a.m. 
Blood concentrations for HDL cholesterol, 
triglycerides, HbA1c, fasting insulin, fibrinogen, high-
sensitivity C reactive protein (hsCRP), creatinine, urea 
nitrogen, and white blood cells count were measured by 
standard procedures. 
 
All centenarians were born in Italy between the 1900 
and 1908. Trained physicians and nursing staff collected 
demographic and lifestyle data, anthropometric 
measurements, functional, cognitive and health status, 
clinical anamnesis, and details on drug use, as 

































SNPs selection. A total of 31 SNPs mapping within and 
nearby 16 different genes (Table S5) were genotyped in 
the 1,349 individuals included in the study. The SNPs 
were selected according to the following criteria: i) 
SNPs reported to be risk factor for T2D [56–62]  such 
as Transcription factor 7-like 2 (TCF7L2), Insulin-like 
growth factor 2 mRNA-binding proteins (IGF2BP), 
Potassium inwardly-rectifying channel, subfamily J, 
member 11 (KCNJ11), Potassium voltage-gated channel 
KQT-like sub-family, member 1 (KCNQ1); ii) SNPs of 
candidate genes for the development of T2D 
complications, such as Catalase (CAT), erythropoietin 
(EPO) [61] , hypoxia-inducible factor 1 α subunit 
(HIF1A) [63]  and DDAH1. Interestingly, significant 
association of CAT and SOD polymorphisms with T2D 
were recently reported [64] . Genetic variations in the 
DDAH1 and DDAH2  genes are significantly associated 
with serum Asymmetric DiMethylArginine (ADMA) 
levels in T2D patients [65]. Moreover, it was reported 
that DDAH gene polymorphisms play a central role in 
determining ADMA in diabetic renal impairment [66]. 
iii) SNPs of genes reported to be involved in metabolic 
diseases, including T2D, such as ADIPOQ and IRS1 
Table 2. Diabetic patients and non diabetic controls collected by the Diabetology Unit in Ancona: samples 
description 
 
































Sex (M/F) 306/258 213/345 … … … … 

















Retinopathy (%) 27.22 % … 27.21 % … 27.24 % … 
Somatic 
Neuropathy (%) 17.79 % … 21.64 % … 13.23 % … 
Renal failure (%) 3.56 % … 4.92 % … 1.94 % … 
Nephropathy (%) 12.81 % … 16.06 % … 8.95 % … 
Ischemic heart 
disease (%) 17.08 % … 20.33 % … 13.23 % … 
Acute myocardial 
infarction (%) 9.07 % … 13.11 % … 4.28 % … 
Ictus (%) 6.76 % … 6.88 % … 6.61% … 
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encoding for adiponectin and insulin receptor substrate 
1 respectively, and FTO, a major gene for obesity 
susceptibility [62–65]. Adiponectin is an adipocyte-
produced protein involved in regulating glucose, lipid 
and energy metabolism, and ADIPOQ polymorphisms 
were previously associated with T2D in Caucasian and 
non-Caucasian populations [59,71,72] . IRS1 
polymorphisms have been associated with risk of T2D 
and adiposity in GWASs. Recently, it was reported that 
IRS1 rs2943641 interacts with carbohydrate and fat 
intakes in incident T2D in a sex-specific manner [73] ; 
iv) SNPs of genes relevant for aging and age-related 
diseases, such as hTERT and TERC, involved in 
telomere stability/attrition and in T2D complications 
[21,74,75] .  
 
SNPs genotyping. DNA was extracted from whole 
blood (QIAmp 96 DNA Blood kit, QIAGEN). 
Genotyping analysis was performed by using 
SEQUENOM MassArray iPLEX technology, following 
the manufacturer’s instructions and as previously 
described [76,77]. Genotype calls were analyzed by 
using SEQUENOM Typer 4.0 software and the 
individual spectrograms were checked in order to 
evaluate the presence of calling errors. 
 
SNP analysis and quality control. Four SNPs 
(rs16889462, rs4880, rs8047395 and rs10434) that did 
not satisfy the Hardy-Weinberg equilibrium (HWE) in 
the control group and five SNPs (rs669173, rs2853669, 
rs3025021, rs13266634 and rs7901695) that showed 
25% missing call rates were excluded from the analysis 
(Table S5). Diabetic patients were also analyzed after 
stratifications for the type of complications (micro and 
macro-vascular). 
 
Only SNPs with call rates higher than 95%, without 
significant deviation from HWE in controls and with 
minor allele frequency (MAF) exceeding 5% were 
retained for the association analysis. Genotypic analysis 
was performed using R 2.15.2 and SNPassoc package 
(http://www.r-project.org/) [78] that implements binary 
logistic regression methods under five different genetic 
models. Allelic association analyses were performed 
using PLINK 1.07, an open-source whole genome 
association analysis toolset (http://pngu.mgh.harvard.edu/ 
purcell/plink/) [71]. 
 
Interactome analysis. Protein-protein interaction (PPI) 
data have been retrieved from the Agile Protein 
Interactions Database APID [80] accessed through the 
dedicated plugin APID2NET [81] and from the 
metadatabase InnateDB [82] and then integrated to form 
the Tcf7l2 interactome (i.e. the set of molecular 
interactions related to Tcf7l2) and analyzed with the 
network analysis platform Cytoscape [83,84]. 
Topological measures such as betweenness centrality 
and node degree are used to rank the importance of the 
interactome elements [85,86]. The betweenness 
centrality of a node reflects the amount of control that 
this node exerts over the interactions of other nodes in 
the network. This measure favors nodes that join 
communities (dense subnetworks), rather than nodes 
that lie inside a community [87,88]. OMIM diseases 
overrepresentation analyses and ranking have been 
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